MBFOPHA@EC2603A(26962.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
MBFOPHA@EC2603A
26962.HK
News
View More

Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial

Fosun Pharmaceutical Gets Nod for Colorectal Cancer Drug Clinical Trial

marketscreener·
HK
02196
+0.89%
SH
600196
-0.22%
marketscreener·
HK
02196
+0.89%
SH
600196
-0.22%

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

Unusual Whales·
SH
600196
-0.22%
HK
02196
+0.89%
Unusual Whales·
SH
600196
-0.22%
HK
02196
+0.89%

Insilico Medicine and Hygtia Therapeutics Launch Joint Development of Brain-Penetrant NLRP3 Inhibitor

Insilico Medicine and Hygtia Therapeutics have formed a global collaboration to co-develop ISM8969, a brain-penetrant NLRP3 inhibitor for CNS diseases. The agreement includes a 50% rights share and potential payments of up to USD 66 million, starting with an initial USD 10 million. Insilico will lead the IND submission and Phase 1 trial for Parkinson’s disease, while Hygtia will handle further development and commercialization. The partnership aims to expedite ISM8969's advancement, which has shown promising preclinical results.

Reuters·
SH
600196
-0.22%
HK
02196
+0.89%
Reuters·
SH
600196
-0.22%
HK
02196
+0.89%

Fosun Pharma Subsidiary’s Lung Cancer Drug Application Accepted by China Regulator

Shanghai Fosun Pharmaceutical's subsidiary, Fosun Wanbang, has had its drug application for Foritinib Succinate Capsules accepted by China's National Medical Products Administration. This drug targets ALK-positive and ROS1-positive non-small cell lung cancer. The acceptance highlights Fosun Pharma's commitment to innovative oncology therapies, potentially enhancing its market position in lung cancer treatment. The current analyst rating for Fosun Pharma's stock (HK:2196) is a Hold with a price target of HK$20.00.

Tip Ranks·
HK
02196
+0.89%
SH
600196
-0.22%
Tip Ranks·
HK
02196
+0.89%
SH
600196
-0.22%

Meow or never: China’s pudgy pets spark race for weight-loss drugs

China's pet obesity crisis is prompting interest in weight-loss drugs for animals, following a $2.1 billion deal between Fosun Pharma's Yao Pharma and Pfizer for an experimental obesity drug. Huadong Medicine is also seeking approval for similar veterinary drugs. The market potential is significant, with 40-50% of pets globally classified as overweight. The growing pet population and increasing humanization of pets are driving demand for advanced therapeutics. However, some pet owners are cautious about potential side effects, preferring dietary management over medication.

南华早报·
SZ
000963
-1.04%
HK
02196
+0.89%
SH
600196
-0.22%
南华早报·
SZ
000963
-1.04%
HK
02196
+0.89%
SH
600196
-0.22%
© 2026 Longbridge｜Disclaimer